Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLS NASDAQ:KROS NASDAQ:MGTX NASDAQ:MRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.57-1.2%$2.25$1.10▼$3.24$142.84M3.03113,774 shs35,096 shsKROSKeros Therapeutics$15.21-0.3%$14.20$9.12▼$72.37$617.75M1.06501,009 shs586,020 shsMGTXMeiraGTx$7.30-2.5%$7.80$3.85▼$8.98$587.29M1.29321,714 shs242,016 shsMRVIMaravai LifeSciences$2.42+1.7%$2.48$1.66▼$9.60$617.98M0.291.46 million shs730,976 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis0.00%-9.82%-12.88%+72.48%+7.08%KROSKeros Therapeutics0.00%-2.25%+6.22%+3.75%-66.46%MGTXMeiraGTx0.00%-6.77%-4.58%+33.70%+79.36%MRVIMaravai LifeSciences0.00%-1.22%+9.01%+13.62%-73.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis2.9877 of 5 stars3.55.00.00.02.22.50.0KROSKeros Therapeutics3.2026 of 5 stars3.32.00.00.03.53.31.3MGTXMeiraGTx4.5617 of 5 stars3.54.00.04.83.22.50.6MRVIMaravai LifeSciences4.0238 of 5 stars3.13.00.04.43.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$4.0055.64% UpsideKROSKeros Therapeutics 2.50Moderate Buy$30.0097.24% UpsideMGTXMeiraGTx 3.00Buy$24.00228.77% UpsideMRVIMaravai LifeSciences 2.18Hold$5.22115.65% UpsideCurrent Analyst Ratings BreakdownLatest CLLS, KROS, MGTX, and MRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.008/12/2025MRVIMaravai LifeSciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$7.00 ➝ $5.008/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $20.006/10/2025KROSKeros TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$32.00 ➝ $18.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$49.22M2.90N/AN/A$2.36 per share1.09KROSKeros Therapeutics$232.84M2.65N/AN/A$14.11 per share1.08MGTXMeiraGTx$33.28M17.65N/AN/A$0.87 per share8.39MRVIMaravai LifeSciences$219.83M2.81$0.62 per share3.92$2.28 per share1.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%11/3/2025 (Estimated)KROSKeros Therapeutics-$187.35M$0.3149.07N/A1.968.06%2.96%2.74%11/5/2025 (Estimated)MGTXMeiraGTx-$147.79M-$2.04N/A19.21N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)MRVIMaravai LifeSciences-$144.85M-$1.36N/AN/AN/A-90.03%-17.60%-9.30%11/6/2025 (Estimated)Latest CLLS, KROS, MGTX, and MRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million8/6/2025Q2 2025KROSKeros Therapeutics-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 million8/4/2025Q2 2025CLLSCellectis-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.581.381.38KROSKeros TherapeuticsN/A21.1121.11MGTXMeiraGTx26.290.880.88MRVIMaravai LifeSciences0.685.164.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%KROSKeros Therapeutics71.56%MGTXMeiraGTx67.48%MRVIMaravai LifeSciences50.25%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%KROSKeros Therapeutics20.60%MGTXMeiraGTx7.50%MRVIMaravai LifeSciences2.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableKROSKeros Therapeutics10040.62 million31.31 millionOptionableMGTXMeiraGTx30080.45 million74.41 millionOptionableMRVIMaravai LifeSciences610255.36 million249.97 millionOptionableCLLS, KROS, MGTX, and MRVI HeadlinesRecent News About These CompaniesVanguard Group Inc. Reduces Stake in Maravai LifeSciences Holdings, Inc. $MRVIAugust 31 at 3:07 AM | marketbeat.comDelta Investment Management LLC Increases Stock Position in Maravai LifeSciences Holdings, Inc. $MRVIAugust 29 at 8:09 AM | marketbeat.comAnalysts Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Price Target at $5.75August 27, 2025 | americanbankingnews.comSystematic Financial Management LP Has $3.40 Million Stock Position in Maravai LifeSciences Holdings, Inc. $MRVIAugust 26, 2025 | marketbeat.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by BrokeragesAugust 26, 2025 | marketbeat.comStock Traders Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)August 23, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 131,492 Shares of Maravai LifeSciences Holdings, Inc. $MRVIAugust 20, 2025 | marketbeat.comMaravai LifeSciences Holdings, Inc. $MRVI Shares Bought by Deutsche Bank AGAugust 19, 2025 | marketbeat.comTejara Capital Ltd Makes New $1.20 Million Investment in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)August 17, 2025 | marketbeat.comMaravai LifeSciences (NASDAQ:MRVI) Shares Gap Up - Time to Buy?August 13, 2025 | marketbeat.comRoyal Bank Of Canada Has Lowered Expectations for Maravai LifeSciences (NASDAQ:MRVI) Stock PriceAugust 13, 2025 | marketbeat.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comMaravai LifeSciences (NASDAQ:MRVI) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPSAugust 12, 2025 | marketbeat.comMaravai Lifesciences price target lowered to $5 from $10 at Craig-HallumAugust 12, 2025 | msn.comMaravai Lifesciences price target lowered to $5 from $7 at RBC CapitalAugust 12, 2025 | msn.comMaravai Lifesciences Announces Major Organizational RestructuringAugust 11, 2025 | msn.comMaravai signals $50M annualized cost reduction plan as leadership targets positive EBITDA in 2026August 11, 2025 | msn.comMaravai LifeSciences Holdings, Inc. (MRVI) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comMaravai LifeSciences Holdings, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 11, 2025 | seekingalpha.comMaravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2025 | zacks.comMaravai LifeSciences Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS, KROS, MGTX, and MRVI Company DescriptionsCellectis NASDAQ:CLLS$2.58 -0.02 (-0.77%) As of 08/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Keros Therapeutics NASDAQ:KROS$15.21 -0.04 (-0.26%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.14 -0.08 (-0.49%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.MeiraGTx NASDAQ:MGTX$7.30 -0.19 (-2.54%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.30 0.00 (0.00%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Maravai LifeSciences NASDAQ:MRVI$2.42 +0.04 (+1.68%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.42 0.00 (-0.21%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
